Secol Antireflux: clinical study on reflux and heartburn

Home / Clinical Studies / Secol Antireflux: clinical study on reflux and heartburn

Secol Antireflux for heartburn and reflux: clinical study results with the GERD-HRQL questionnaire

Secol Antireflux for reflux and heartburn is designed to support the management of common gastroesophageal reflux symptoms: acid regurgitation, heartburn, discomfort when lying down, night-time awakenings and, when associated, reflux-related cough and bloating.

In the clinical study, changes in symptoms were assessed using the GERD-HRQL questionnaire, a tool used in clinical research to systematically assess the impact of reflux on quality of life.

Secol Antireflux is available as an oral gel in 210 ml or 300 ml bottles, supplied with a syringe adapter and a dosing syringe.

All our medical devices for managing gastroesophageal reflux are under MDD extension, reflecting a structured regulatory and qualification programme in the GERD area.

The data refer to an observational clinical study conducted by Gruppo Farmaimpresa in August 2025, evaluating Secol Antireflux in the management of gastroesophageal reflux symptoms and heartburn and assessing their impact on quality of life using a dedicated clinical questionnaire.

What is Secol Antireflux and how does it differ from a simple antacid?

Secol Antireflux is an oral gel containing magnesium alginate and simethicone, designed to support people who occasionally experience symptoms of gastroesophageal reflux.

It combines two complementary physical mechanisms in a dual-action system:

  • Magnesium alginate: helps form a protective barrier, helping counter acid regurgitation.
  • Simethicone: reduces the surface tension of gas bubbles in gastric contents, facilitating their elimination and providing support when reflux is accompanied by bloating and abdominal distension.

Who is Secol Antireflux indicated for?

Secol Antireflux supports the management of recurring discomfort caused by reflux and excess acidity, which can affect everyday well-being and sleep. It is particularly relevant when typical reflux symptoms are accompanied by bloating, gas, abdominal heaviness and tension.

Indications include:

  • Gastroesophageal reflux disease (GERD)
  • Reflux esophagitis
  • Heartburn
  • Reflux-related cough
  • Abdominal pain or cramps associated with excess acidity and bloating.

Secol Antireflux clinical study: methodology and results

Secol Antireflux GERD-HRQL scores at baseline and after four weeks
Comparison of GERD-HRQL scores at baseline and after four weeks.

The observational study enrolled 20 adults. Symptoms were reassessed at follow-up after 4 weeks (T1) and compared with baseline (T0). During the study, the daily dose was 15 ml.

The GERD-HRQL score chart shows a marked reduction between T0 and T1, with a statistically significant difference (p < 0.001). This reflects an observed improvement in typical reflux symptoms, including heartburn and associated discomfort, and in quality of life.

How much did patients improve?

The report indicates that 75% of patients achieved a reduction of at least 50% in their GERD-HRQL score. With one exception, participants also reduced their scores to lower severity levels.

Specific symptoms: what changed in everyday life?

In addition to the overall score, the report highlights a substantial decrease in symptom frequency. In particular, night-time awakenings due to heartburn, difficulty swallowing and pain when swallowing were almost completely absent at follow-up (T1). Overall health perception also improved, with many participants moving from dissatisfaction to a satisfied or neutral assessment. As this was an observational study without a control group, the findings cannot establish causality.

Looking for a ready-to-market or private label solution for B2B distribution?

We are certified manufacturers of medical devices, food supplements and cosmetics. Secol Antireflux is available for market launch or private label, with regulatory and clinical support.

Contact us

Share:

More Posts:

Send Us A Message

Subscribe to our Newsletter